The Company's long-term vision is to radically improve treatment of a variety of infectious diseases with efficacious new class of antibiotics that have a novel mechanism of action. Our small molecule compound candidates act on multiple and different bacterial cell-pathways and have broad market potential, with applications in multiple clinical indications. Our current antibiotic pipeline includes few hit candidates and back-up compounds that address serious, life-threatening infectious diseases. We are developing a class of antibacterial agents that shows promising in vitro safety and efficacy activities as new broad spectrum antibiotics (inhibiting both gram-positive and gram-negative microbes). Our most recent anti-infective drug discovery effort is concentrated on gram negative pathogens: Pseudomonas aeruginosa, Acinetobacter, and Enterobacteriaceae such as Klebsiella pneumonia and Escherichia coli.
Bioxiness Pharmaceuticals is developing novel small molecule therapeutics to treat a variety of infectious diseases. Our Drug Discovery Programs identify new scaffolds with antibacterial activity, and compound libraries are prepared around each active scaffold using focused synthetic medicinal chemistry. Bioxiness scientists developed and validated several screening assays that are used to analyze the libraries for target pathogen activity and are in the process of identifying the most promising compounds for pre-clinical development.